Clinical Trials Sponsored by Abcentra

Total 22 results

Abcentra

Completed

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Coronary Artery Disease | Inflammation | Psoriasis | Cardiometabolic Syndrome

United States
Accentia Biopharmaceuticals

Completed

Amphotericin B Suspension in Refractory Chronic Sinusitis

Chronic Sinusitis

United States
Ascenta Therapeutics

Completed

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Hormone Refractory Prostate Cancer

United States
Ascenta Therapeutics

Terminated

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Locally Advanced Esophageal or GE Junction Cancer

United States
Ascenta Therapeutics

Completed

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Prostate Cancer

United States
Ascenta Therapeutics

Completed

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States, Russian Federation, Ukraine
Ascentia Health, Inc.

Completed

Treatment Outcomes for Temporomandibular Disorders (TMD) Via the Clayton Intra-aural Device (CID) Clinical Trial

Temporomandibular Disorders

Mexico
Adcentrx Therapeutics

Recruiting

A Study of ADRX-0706 in Select Advanced Solid Tumors

Solid Tumors

United States
Ascenta Therapeutics

Completed

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | Small Lymphocytic Lymphoma

United States
Ascenta Therapeutics

Completed

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Hormone Refractory Prostate Cancer

United States, Russian Federation
Ascenta Therapeutics

Completed

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
Ascenta Therapeutics

Completed

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Russian Federation, United States, Ukraine
Ascenta Therapeutics

Completed

Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Axcentua Pharmaceuticals AB

Unknown

AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

Adenocarcinoma

Sweden
Seneque SA
Dicentra Inc.; LGD

Completed

Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.

Healthy Volunteers

Canada
Immunoflex Therapeutics Inc.
University of British Columbia; Dicentra Inc.

Completed

Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants

Immunity Disorders

Canada
Memorial Sloan Kettering Cancer Center
Ascenta Therapeutics

Terminated

Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Lung Cancer

United States
University of Alabama at Birmingham
Ascenta Therapeutics

Withdrawn

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

Carcinoma, Non Small Cell Lung
Ascenta Therapeutics
The Leukemia and Lymphoma Society

Terminated

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia (AML)

United States
The Canadian College of Naturopathic Medicine
Wakunaga Pharmaceutical Co., Ltd.; Dicentra Inc.

Completed

Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)

Digestive System Diseases | Irritable Bowel Syndrome | Colonic Diseases, Functional | Colitis, Mucous | Colon, Irritable

Canada
The Canadian College of Naturopathic Medicine
Wakunaga Pharmaceutical Co., Ltd.; Dicentra Inc.

Completed

Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)

Digestive System Diseases | Irritable Bowel Syndrome | Colonic Diseases, Functional | Colitis, Mucous | Colon, Irritable

Canada
University Medical Center Groningen
Netherlands Heart Foundation; Disphar International B.V.; Teva Nederland BV; Tiofarma... and other collaborators

Active, not recruiting

Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands (DECISION)

Heart Failure

Netherlands

Clinical Trials Sponsored by Abcentra

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations